Announcement
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
I-Mab
PR-10-24-NI-80Nov 07, 2024
Partnership
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie
PR-M09-20-NI-06Sep 04, 2020
Strategic Partnership
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs
WuXi Biologics
PR-M04-19-NI-065Apr 19, 2019
FDA Approval
I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody
I-Mab
PR-M01-19-NI-082Jan 29, 2019
Immunotherapy
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy
I-Mab
PR-M11-18-NI-014Nov 05, 2018
Global Collaboration
ABL Bio and I-Mab Biopharma Announce Global Collaboration on Innovative Bispecific Antibodies
ABL Bio
PR-M08-18-NI-005Aug 01, 2018
Global Collaboration
I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies
I-Mab
PR-M07-18-NI-107Jul 31, 2018